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Despite an increasing number of reports, there is no
consensus on the pathologic diagnostic criteria of
MPNSTs [1]. MPNSTs have several synonyms, including
neurofibrosarcoma and malignant schwannoma [2,3].
They may arise de novo or be associated with von
Recklinghausen’s disease (neurofibromatosis 1) (NF1) [3].
They compose 5–10% of all soft tissue sarcomas [2,4]. Many
studies have appeared about immunohistochemical and
molecular analysis, and have made dramatic progress in
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Because there are no standardized radiologic and histologic criteria, the differential diagnosis of malignant
peripheral nerve sheath tumors (MPNSTs) from other spindle cell neoplasms poses great challenges for
pathologists. Because early diagnosis of MPNSTs arising from benign peripheral nerve sheath tumors
(BPNSTs) means a better prognosis, many immunohistochemical and molecular studies have recently
emerged. Nevertheless, no gold standard diagnostic criterion is to be found in the literature. For example,
S-100 protein is widely used in the diagnosis of MPNST. Other promising ancillary markers are p53 and
Ki-67; however, the staining patterns and possible mechanisms of these markers are seldom mentioned in the
literature. These evoke our interest. Only six cases diagnosed as MPNST were retrieved from the archives of
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September 2005. Clinical files were available for three of them, and we found nuances in the immunohistochemistry
from these previous reports. Here, we present these rare sarcomas and review the literature.
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this field. High levels of p53 and Ki-67 exist in MPNSTs, and
their use may aid in the detection of early malignant
transformation [5]. More frequent accumulation of p53 in
NF1-associated MPNSTs is also found and, hence, may
account for the poor prognosis [6]. Low-grade MPNSTs
display diffuse or focal S-100 reactivity, whereas most
high-grade ones show decreased or negative S-100
reactivity [7]. Some investigators have tried to explain the
different intensity and staining patterns in BPNSTs, and
in low- and high-grade MPNSTs. It has been suggested
that lack of S-100 reactivity in most cases probably reflects
a low degree of differentiation [8]. However, one of our
cases did not conform totally to our expectations in light of
these patterns. Three cases of MPNSTs are described (Tables
1 and 2).
© 2006 Elsevier. All rights reserved.
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CASE PRESENTATION
Case 1
Patient 1, a 59-year-old female with no family history of
NF1, developed an acute onset of low back pain and
myoclonic movement of the left limbs not associated with
conscious change, tonic gazing, and trismus. She had had
hypertension for years with regular control, an intracranial
hemorrhage 18 years ago, left hemiparesis since that episode,
and uterine myoma without pathologic proof for nearly 4
years. Magnetic resonance imaging (MRI) disclosed multiple
metastatic lesions at both hepatic lobes and bone. Abdominal
computed tomographic (CT) scans revealed a 10-cm mass
in the uterus. The lesion on L2 spine was explored surgically,
and excision biopsy was subsequently performed. She
refused further treatment and was lost to follow-up. The
excised surgical specimen consisted of five solid gray-tan
fragments of tissue measuring as large as 2.5 × 2 × 0.8 cm in
size. Microscopic examination revealed an alternately
hypercellular and hypocellular tumor destroying bone and
soft tissue. The tumor cells had plump oval, round, spindle,
to wavy nuclei in a fascicular pattern. Pleomorphism,
necrosis, focal hyalinization, and frequent mitoses (as many
as 33 mitoses per ten high-power fields (HPF) were identified
(Figure 1A). Immunohistochemical testing showed diffuse
S-100 staining and focal positive neuron-specific enolase
(NSE) (50%), neurofilament protein (NFP) (2.5%), smooth
muscle actin (SMA) (7.5%), and cytokeratin 7 (CK7)(2.5%),
whereas CD34, desmin, CD117, and epithelial membrane
antigen (EMA) were all negative (Figure 1B). There was
substantial Ki-67 and p53 overexpression (mean 55.28%
and 36%, respectively) (Figures 1C and 1D).
Case 2
Patient 2, an 82-year-old male with a history of gastric
cancer and subsequent surgery, developed a mild tender
mass palpable in the right axilla. MRI demonstrated a huge
ovoid lesion. It was inhomogeneous and had a high T1W
signal (Figure 2), a high T2W rim, and a low T2W center.
Surgery was performed in 2002. Surgery demonstrated a
10-cm elastic and movable mass with adhesion to nerve and
vessels. The soft tissue around the lesion was swollen and
rich in vascularity. Although the surgeon removed as much
of the tumor as possible, the lesion soon recurred. He had
five courses of radiotherapy and chemotherapy. We were
unable to follow up the patient approximately 1 year ago.
Table 1. Summary of the clinical files
Patient 1 Patient 2 Patient 3
Gender Female Male Male
Age (years) 59 82 49
Tumor site Pelvic Right axilla S1 and S2
Metastasis + – +
Local recurrence – + +
Follow-up period 1 month 10 years, 9 months 1 year
Table 2. Comparison between histologic features and immunohistochemical results
Patient 1 Patient 2 Patient 3
Cellularity* 3 2 1
Mitoses 33/10 HPF 6/10 HPF 4/10 HPF
Necrosis + + +
S-100 + (almost 100%) + (40%) – (totally negative)
p53 (%) 36 28 0
Ki-67 (%) 55 10 2
NSE (%) + (50) + (50) + (10)
SMA (%) + (7.5) < 1, weak 1, weak
Desmin – – –
HPF = high power field; NSE = neuron-specific enolase; SMA = smooth muscle actin.
*Cellularity in order; 1 = the highest cellularity among the three.
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The excised specimen for frozen section consisted of
one gray-tan tissue fragment, measuring 2.2 × 1.5 ×
0.6 cm. The specimen submitted later consisted of one
well-circumscribed tissue fragment and measured 6 × 6 ×
5 cm. The cut surface was tan-yellow with focal myxoid
change and necrosis. Microscopic sections showed
alternate hypercellular and hypocellular myxoid zones.
It revealed patternless and interlacing fascicle with focal
neurofibroma background. Tumor cells showed ovoid,
wavy, or spindle nuclei with frequent bizarre cells,
increased mitotic activity (6/10 HPF), and necrosis
(Figure 3A). Immunohistochemical studies showed
focal immunoreactivity of S-100 (40%) and NSE (50%)
(Figure 3B). Staining for CD34, SMA, and desmin
was negative. Interspersed collagen was demonstrated
focally by Masson’s trichrome stain. There was
overexpression of p53 (mean 28%) and Ki-67 (mean 10%)
(Figures 3C and 3D).
Figure 1. Microscopic appearances. (A) The hypercellular tumor exhibited atypism and bizarre tumor giant cells (hematoxylin & eosin stain,
original magnification × 400). (B) Diffuse S-100 immunopositivity (immunohistochemical stain, original magnification × 400 ). (C) Higher p53
overexpression (immunohistochemical stain, original magnification × 400 ). (D) Higher Ki-67 index (immunohistochemical stain, original
magnification × 400).
Figure 2. The T1-weighted coronal section demonstrates an
inhomogeneous but relatively well-circumscribed lesion with
surrounding edematous soft tissue.
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Case 3
Patient 3, a 49-year-old man without NF1, complained of
right gluteal soreness with radiation to the lower leg since
January 1997. He sought treatment in another hospital, and
an invasive tumor mass in the sacrum was found. The
pathologic specimen after surgery revealed a malignant
schwannoma. He came to our hospital because of recurrence
of sarcoma. He had six courses of radiotherapy and
chemotherapy. We have been unable to follow up this
patient in our clinic since April 1998. The surgical specimen
of the recurrent tumor consisted of multiple gray-white
fragments of tissue, measuring as large as 2 × 1.8 × 0.9 cm.
The histopathologic appearance was of a highly
hypercellular, mitotically active (4/10 HPF), spindle cell
neoplasm with short interlacing fascicles. There were nuclear
atypia with occasionally large bizarre cells and necrosis
(Figure 4A). The immunohistochemical panel showed
positive NSE (80%) and focal weak positive SMA (33%).
The S-100, desmin, NFP, and p53 all stained negatively
(Figures 4B and 4C). No collagen was found by Masson’s
trichrome stain. Low Ki-67 expression was seen (mean 2%)
(Figure 4D).
DISCUSSION
Most MPNSTs are well circumscribed but not truly
encapsulated [9].The highly aggressive sarcomas are
believed to be derived from components of the nerve sheath
and may occur in any part of the body [10,11], although the
retroperitoneum is a rare site [11]. Patient 1 had a huge
pelvic mass. To the best of our knowledge, this is a rare case
report. The standard diagnostic criterion is still enigmatic,
as is reflected in the diverse histologic subtypes [10–12].
Figure 3. Microscopic appearances. (A) Higher cellularity and more bizarre tumor cells than in patient 1 with short fascicular growth pattern.
(hematoxylin & eosin stain, original magnification × 40). (B) S-100 reveals partially immunoreactive (immunohistochemical stain, original
magnification × 100). (C) High p53 overexpression. (immunohistochemical stain, original magnification × 200). (D) High Ki-67 index
(immunohistochemical stain, original magnification × 400).
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Some authors have described low-grade and high-grade
MPNSTs, whereas others have described well-differentiated
and anaplastic MPNSTs [6,12]. These subcategories are not
generally accepted. The diagnosis is facilitated by typical
features such as palisading arrangement, nuclear atypia,
bizarre giant cells, mitotic figures, and necrosis [13].
However, equivocal features may be encountered, and the
differential diagnosis includes benign nerve sheath
tumors and other spindle cell sarcomas [12]. The main
differential diagnosis encompasses hemangiopericytoma,
angiosarcoma, leiomyosarcoma, and malignant melanoma
[ 1 2 , 1 4 ] .  T h e r e  h a v e  b e e n  s e v e r a l  p r o m i s i n g
immunohistochemical markers [5,15]. Among these, S-100,
p53, and Ki-67 attracted our attention. Although S-100 is
widely used and valuable in the diagnosis of MPNSTs,
there are no specific markers [14]. S-100 is highly
characteristic of neural-derived neoplasms, but it is also
Figure 4. (A) The highest cellularity and more bizarre tumor cells than in patients 1 and 2. It demonstrates typical palisading around necrosis.
(hematoxylin & eosin stain, original magnification × 40). (B) Totally negative S-100 (immunohistochemical stain, original magnification × 400).
(C) No p53 overexpression (immunohistochemical stain, original magnification × 200). (D) No Ki-67 expression in this field (immunohistochemical
stain, original magnification × 400).
expressed in a wide range of tissues [16,17]. S-100 is positive
in 83% of BPNSTs and shows intensely positive with no
relation to cell morphology [16]. Only 50–60% of MPNSTs
express S-100 [18]. The most challenging of all is the method
of diagnosing MPNST with a negative stain for S-100 as in
our patient 3. We reviewed the literature and found that
S-100 expression in MPNSTs is usually weak and focal,
whereas BPNSTs demonstrate strong S-100 staining [10,19].
Our patient 1 showed strong and diffusely positive S-100
expression, which was not in accordance with the reports
[10,19]. The staining pattern of S-100 varies greatly. What
mechanism causes such great variation? Does S-100 play an
important role in the ancillary studies? Some authors have
proposed that S-100 negativity in most MPNSTs probably
reflects their low degree of differentiation [8]. We decided
to test the notion that, if S-100 is associated with the
differentiation of MPNSTs, S-100 staining might predict
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clinical behavior. We retrieved and analyzed the files of the
Department of Pathology, Kaohsiung Medical University
Chung-Ho Memorial Hospital between 1988 and September
2005. Only six patients diagnosed with MPNST were
obtained, and three of these were lost to hospital records.
We found that these three patients all had high-grade
histologic results. According to the literature [10,19],
S-100 staining should be focal and weakly positive; however,
the specimen from patient 1 showed diffusely positive
staining and that from patient 3 was totally negative. These
findings were not in accordance with the concept that
negative S-100 staining represents dedifferentiation of
Schwann cells [20]. S-100 expression might be related to the
predominantly neoplastic cells in MPNSTs, because they
might have diverse differentiation [16]. This might
reasonably explain the phenomenon we observed, although
the study has the limitation of the limited number of
patients. A large-scale study will be necessary to determine
if the S-100 staining pattern could reflect the degree of
differentiation or predict the clinical behavior.
p53 expression also plays an important role in the
tumorigenesis of MPNSTs [21]. In addition to p53, Ki-67
expression also figures prominently in differentiating
between the diagnoses of BPNST and MPNST [6,22,23].
Patients 1 and 2 had high Ki-67 and p53 expression as in the
previous reports (Table 2) [6,22,23]. However, patient 3 had
2% immunoreactivity of Ki-67 and no p53 overexpression.
Histopathologically speaking, patient 3 had the highest
cellularity, more bizarre cells, and the presence of a more
typical palisading pattern in the peripheral area of necrosis.
Patient 2 had a higher histologic grade than patient 1.
However, the expression of p53 and Ki-67 was inversely
related to the histologic grade, a most unexpected result.
It seems that p53 and Ki-67 do not correspond with the
histologic grade, although they may be relevant to the
differentiation of BPNSTs from MPNSTs [6]. Moreover,
we found that patients 1 and 3 had distal metastases,
whereas patient 2 had local recurrence. It seems that Ki-67,
p53, and histologic grade do not correlate with clinical
behavior. Another problem lies in how to differentiate
MPNSTs from BPNSTs if the ancillary studies of p53 and
Ki-67 are not contributory. In such instances, other
supplementary studies such as cytogenetic analysis are
necessary [2].
Morphologic imaging techniques provide better
visualization of the anatomic extent, and MRI is the first
choice [24,25]. The MRI findings in our patients are
heterogeneous because of necrosis; this is compatible with
the nonhomogeneous lesions in the documented cases
[26,27]. However, MRI is not a reliable tool for distinguishing
benign and malignant nerve sheath tumors [27].
MPNSTs have a poor prognosis [28]. They can locally
recur or metastasize to distant sites [29,30]. Sufficiently
wide local excision is necessary, but this is restricted mostly
by tumor location [29–31]. Furthermore, radiotherapy and
chemotherapy are also used [31,32], but they have not, as
yet, been proven to be totally effective [29–33]. With the
advent of imaging techniques and immunohistochemistry,
pathologists have come to rely on them. They seem to
eclipse the traditional pathologic examination. With the
nuance of the immunohistochemical staining pattern
in our cases, we still believe that traditional histologic
assessment is the mainstay of pathologic diagnosis. The
combination application of Ki-67 and p53 are best regarded
as an ancillary technique and should not supersede
the traditional pathologic examination [34]. Because of
short clinical follow-up and inadequate samples, a
meaningful relationship between immunohistochemistry,
histopathologic grade, and clinical behavior is not possible.
Probably as a result of the rarity of MPNSTs, there have
been few reports with longer clinical follow-up and more
patient samples. A large-scale study is required to explain
these findings.
REFERENCES
1. Perrin RG, Guha A. Malignant peripheral nerve sheath tumors.
Neurosurg Clin N Am 2004;15:203–16.
2. McComb EN, McComb RD, DeBoer JM, et al. Cytogenetic
analysis of a malignant triton tumor and a malignant peripheral
nerve sheath tumor and a review of the literature. Cancer Genet
Cytogenet 1996;91:8–12.
3. Colville RJ, Camilleri IG, McLean NR, et al. Malignant
peripheral nerve sheath tumour metastasising to the parotid
gland. Br J Plast Surg 2003;56:418–20.
4. Bagan JV, Sanchis JM, Jimenez Y, et al. Malignant peripheral
nerve sheath tumor of the maxilla. Oral Oncol Extra 2005;41:
70–3.
5. Kindblom LG, Ahlden M, Meis-Kindblom JM, et al.
Immunohistochemical and molecular analysis of p53, MDM2,
proliferating cell nuclear antigen and Ki67 in benign and
malignant peripheral nerve sheath tumours. Virchows Arch
1995;427:19–26.
6. Liapis H, Marley EF, Lin Y, et al. p53 and Ki-67 proliferating cell
nuclear antigen in benign and malignant peripheral nerve
sheath tumors in children. Pediatr Dev Pathol 1999;2:377–84.
7. Zhou H, Coffin CM, Perkins SL, et al. Malignant peripheral
nerve sheath tumor: a comparison of grade, immunophenotype,
and cell cycle/growth activation marker expression in sporadic
and neurofibromatosis 1-related lesions. Am J Surg Pathol 2003;
27:1337–45.
Immunoprofiles in malignant peripheral nerve sheath tumor
Kaohsiung J Med Sci March 2006 • Vol 22 • No 3 141
8. Koizumi Y, Utsunomiya T, Yamamoto H. Cellular
schwannoma in the oral mucosa. Acta Otolaryngol 2002;122:
458–62.
9. Aydin MD, Yildirim U, Gundogdu C, et al. Malignant
peripheral nerve sheath tumor of the orbit: cases report and
literature review. Skull Base 2004;14:109–13.
10. Garg A, Gupta V, Gaikwad SB, et al. Scalp malignant peripheral
nerve sheath tumor (MPNST) with bony involvement and
new bone formation: case report. Clin Neurol Neurosurg 2004;
106:340–4.
11. Oguzkurt P, Kayaselcuk F, Arda IS, et al. Anterior abdominal
wall malignant peripheral nerve sheath tumor in an infant.
J Pediatr Surg 2001;36:1866–8.
12. Klijanienko J, Caillaud JM, Lagacé R, et al. Cytohistologic
correlations of 24 malignant peripheral nerve sheath tumors
(MPNST) in 17 patients: the Institut Curie experience. Diagn
Cytopathol 2002;27:103–8.
13. Legbo JN, Shehu BB, Malami SA. Malignant peripheral nerve
sheath tumour associated with von Recklinghausen’s disease:
case report. East Afr Med J 2005;82:47–9.
14. Nkere UU, Walter NM. Malignant peripheral nerve sheath
tumour: a rare tumor and an unusual intrapericardial
presentation. Eur J Cardiothorac Surg 1997;12:144–6.
15. Matsuda Y, Saoo K, Hosokawa K, et al. Epithelioid malignant
peripheral nerve sheath tumor. Report of a case with
inflammatory infiltration. Pathol Res Pract 2005;201:355–60.
16. Chijiwa K, Uchida K, Tateyama S. Immunohistochemical
evaluation of canine peripheral nerve sheath tumors and
other soft tissue sarcomas. Vet Pathol 2004;41:307–18.
17. Weiss SW, Langloss JM, Enzinger FM. Value of S-100 protein
in the diagnosis of soft tissue tumors with particular reference
to benign and malignant Schwann cell tumors. Lab Invest 1983;
49:299–308.
18. Smith TA, Machen SK, Fisher C, et al. Usefulness of cytokeratin
subsets for distinguishing monophasic synovial sarcoma from
malignant peripheral nerve sheath tumor. Am J Clin Pathol
1999;112:641–8.
19. Molina CP, Putegnat BB, Logrono R. Fine-needle aspiration
cytology and core biopsy of malignant peripheral nerve sheath
tumor of the uterus: a case report. Diagn Cytopathol 2001;24:
347–51.
20. Gonzalez-Martinez T, Perez-Piñera P, Díaz-Esnal B, et al.
S-100 proteins in the human peripheral nervous system. Microsc
Res Tech 2003;60:633–8.
21. Mawrin C, Kirches E, Boltze C, et al. Immunohistochemical
and molecular analysis of p53, RB, and PTEN in malignant
peripheral nerve sheath tumors. Virchows Arch 2002;440:
610–5.
22. Halling KC, Scheithauer BW, Halling AC, et al. p53 expression
in neurofibroma and malignant peripheral nerve sheath tumor.
An immunohistochemical study of sporadic and NF1-
associated tumors. Am J Clin Pathol 1996;106:282–8.
23. Antinheimo J, Haapasalo H, Seppala M, et al. Proliferative
potential of sporadic and neurofibromatosis 2-associated
schwannomas as studied by MIB-1(ki-67) and PCNA labeling.
J Neuropathol Exp Neurol 1995;54:776–82.
24. Otsuka H, Graham MM, Kubo A, et al. PDG-PET/CT findings
of sarcomatous transformation in neurofibromatosis: a case
report. Ann Nucl Med 2005;19:55–8.
25. Huang JH, Zhang J, Zager EL. Diagnosis and treatment options
for nerve sheath tumors. Expert Rev Neurother 2005;5:
515–23.
26. Friedrich RE, Kluwe L, Funsterer C, et al. Malignant peripheral
nerve sheath tumors (MPNST) in neurofibromatosis type 1
(NF1): diagnostic findings on magnetic resonance images and
mutation analysis of the NF1 gene. Anticancer Res 2005;25:
1699–702.
27. Mautner VF, Friedrich RE, von Deimling A, et al. Malignant
peripheral nerve sheath tumours in neurofibromatosis type 1:
MRI supports the diagnosis of malignant plexiform
neurofibroma. Neuroradiology 2003;45:618–25.
28. Tucker T, Wolkenstein P, Revuz J, et al. Association between
benign and malignant peripheral nerve sheath tumors in NF1.
Neurology 2005;65:205–11.
29. Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral
nerve sheath tumor: the clinical spectrum and outcome of
treatment. Neurology 2003;61:696–8.
30. Doorn PF, Molenaar WM, Buter J, et al. Malignant peripheral
nerve sheath tumors in patients with and without
neurofibromatosis. Eur J Surg Oncol 1995;21:78–82.
31. Mrugala MM, Batchelor TT, Plotkin SR. Peripheral and cranial
nerve sheath tumors. Curr Opin Neurol 2005;18:604–10.
32. Wanebo JE, Malik JM, VandenBerg SR, et al. Malignant
peripheral nerve sheath tumors. A clinicopathologic study of
28 cases. Cancer 1993;71:1247–53.
33. Satoh M, Komori K, Shin M, et al. Retroperitoneal malignant
peripheral nerve sheath tumor (MPNST) complicated with
von Recklinghausen’s disease: a case report. Hinyokika Kiyo
2004;50:417–20.
34. Pfeifer JD, Hill DA, O’Sullivan MJ, et al. Diagnostic gold
standard for soft tissue tumours: morphology or molecular
genetics? Histopathology 2000;37:485–500.
˘ ¸
˘
142 Kaohsiung J Med Sci March 2006 • Vol 22 • No 3
 !"#$%&'=pJNMM=
 !"#$%&'()*+,
 !"#$%&'(
 
NIO
= = 
P
= = 
Q
= = 
R
= = 
NIO
 !"!#$%&'( )=
N
 =
P
 !"=
Q
 !"#=
R

O
 !"!= !"#$
 !"#$%&'()*+,-./01)*2345/6789:;<=>?
 !"#$%%&'()*+,-./01234567#829:$
 !"#$%&'()"*+,-./012/"34567$89:";<=
 !"#$%&'()*+,-./pJNMM= !"#$%&'()*+,
 !"#$%= éRP== háJST= !"#$%&'()*+),-./!
 !"#$%&'() *+,-./012 34,256789:;:
 !"#$%&'()*+,=NVUU==OMMR= !"#$%&'()*
 !"#$%&'()*+,-./(0123456789:;<=>?@A
 !"#$%&'()*+,-./01234)56789:;<=>
 ! !"#$%&'pJNMMéRPháJST
 !"=OMMSXOOWNPRJQO
 !"VQ==NM==OS=
 !"VQ==NO==NR=
 !"#$%&'
 !"!#$%&'( )*+,
 !"#$%&'()=NMM=
